Cangrealor is the first FDA-approved P2Y12 inhibitor.
Joseph E. Cruz, Pharm.D., BCPS
Advertisement
Joseph E. Cruz, Pharm.D., BCPS is Clinical Assistant Professor at Rutgers University, and The State University of New Jersey Clinical Coordinator - Internal Medicine Englewood Hospital and Medical Center.
Articles by Joseph E. Cruz, Pharm.D., BCPS
The first of their kind, evolocumab and alirocumab belong to a new class of cholesterol lowering agents.
Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.
Advertisement
Latest Updated Articles
- PCSK9 Inhibitors: The First of Their Kind
Published: January 26th 2017 | Updated:
- Cardiac Matters
Published: March 15th 2017 | Updated:
- New combo therapy for chronic heart failure
Published: December 15th 2016 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Severe COVID-19 Increases Stroke Risk for Patients With Asthma
2
Coming Full Circle: How Mike Brundage Built a Thriving Pharmacy in Rural Pennsylvania
3
Pharmacists Help Patients Stay Adherent to COPD Therapy, Improving Overall Quality of Life
4
FDA Approves First 1-Minute Self Test for HIV
5
